AbbVie Inc.
ABBV Healthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 290.4%, free cash flow fell 36.2% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.
Follow ABBV
AbbVie Inc. (ABBV) Revenue
AbbVie Inc.'s revenue for fiscal 2025 was $61.2B, up 8.57% from $56.3B in fiscal 2024. Over the twelve months to 30 June 2026 it was $64.4B. Over the past ten years it has ranged from $22.9B (fiscal 2015) to $61.2B (fiscal 2025) — the current reading is the highest in ten years. AbbVie Inc. ranks 4th of 18 Drug Manufacturers General companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $61.2B | 8.57% |
| FY2024 | $56.3B | 3.71% |
| FY2023 | $54.3B | (6.44%) |
| FY2022 | $58.1B | 3.30% |
| FY2021 | $56.2B | 22.69% |
| FY2020 | $45.8B | 37.69% |
| FY2019 | $33.3B | 1.57% |
| FY2018 | $32.8B | 16.08% |
| FY2017 | $28.2B | 10.06% |
| FY2016 | $25.6B | 12.16% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $17.0B | 13.25% |
| Mar 2026 | $15.0B | (9.72%) |
| Dec 2025 | $16.6B | 5.34% |
| Sep 2025 | $15.8B | 2.29% |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| JNJ Johnson & Johnson compare | $99.3B |
| LLY Eli Lilly and Company compare | $79.7B |
| MRK Merck & Co., Inc. compare | $66.6B |
| ABBV AbbVie Inc. | $64.4B |
| PFE Pfizer Inc. compare | $63.7B |
| AZN AstraZeneca PLC compare | $61.4B |
| NVS Novartis AG compare | $56.7B |
| AMGN Amgen Inc. compare | $38.1B |
| GILD Gilead Sciences, Inc. compare | $30.5B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on ABBV
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement